Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02REJ
|
||||
| Former ID |
DIB011251
|
||||
| Drug Name |
JNJ-17216498
|
||||
| Synonyms |
Histamine H3 antagonist (oral, narcolepsy) J&J
|
||||
| Indication | Narcolepsy [ICD9: 347; ICD10:G47.4] | Phase 2 | [1] | ||
| Company |
Johnson & Johnson
|
||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00424931) A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy. U.S. National Institutes of Health. | ||||
| REF 2 | Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61. Epub 2004 Oct 4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.